European Journal of Therapeutics, vol.27, no.4, pp.311-317, 2021 (Peer-Reviewed Journal)
Article / Article
European Journal of Therapeutics
Emerging Sources Citation Index, TR DİZİN (ULAKBİM)
COVID-19, corrected QT, hydroxychloroquine, azithromycin, favipiravir, RISK
Objective: We aimed to evaluate the degree of QTc prolongation and associated factors in patients with COVID-19 in association with their usage of hydroxychloroquine (HCQ) with or without the combination of azithromycin (AZ) and/or favipiravir (FAV).